- Home
- TOYO vs SGHT Comparison
TOYO vs SGHT Comparison
Compare TOYO & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- SGHT
- Stock Information
- Founded
- TOYO 2022
- SGHT 2011
- Country
- TOYO Japan
- SGHT United States
- Employees
- TOYO N/A
- SGHT 216
- Industry
- TOYO
- SGHT Medical Specialities
- Sector
- TOYO
- SGHT Health Care
- Exchange
- TOYO NYSE
- SGHT Nasdaq
- Market Cap
- TOYO 131.2M
- SGHT 157.7M
- IPO Year
- TOYO N/A
- SGHT 2021
- Fundamental
- Price
- TOYO $3.02
- SGHT $3.03
- Analyst Decision
- TOYO
- SGHT Buy
- Analyst Count
- TOYO 0
- SGHT 7
- Target Price
- TOYO N/A
- SGHT $3.92
- AVG Volume (30 Days)
- TOYO 10.1K
- SGHT 161.2K
- Earning Date
- TOYO 04-28-2025
- SGHT 05-08-2025
- Dividend Yield
- TOYO N/A
- SGHT N/A
- EPS Growth
- TOYO N/A
- SGHT N/A
- EPS
- TOYO 0.76
- SGHT N/A
- Revenue
- TOYO $200,455,385.00
- SGHT $78,109,000.00
- Revenue This Year
- TOYO N/A
- SGHT N/A
- Revenue Next Year
- TOYO N/A
- SGHT $11.17
- P/E Ratio
- TOYO $3.95
- SGHT N/A
- Revenue Growth
- TOYO N/A
- SGHT N/A
- 52 Week Low
- TOYO $1.36
- SGHT $2.03
- 52 Week High
- TOYO $15.61
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- SGHT 56.13
- Support Level
- TOYO N/A
- SGHT $2.81
- Resistance Level
- TOYO N/A
- SGHT $3.26
- Average True Range (ATR)
- TOYO 0.00
- SGHT 0.24
- MACD
- TOYO 0.00
- SGHT -0.01
- Stochastic Oscillator
- TOYO 0.00
- SGHT 38.57
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.